Advertisement

Journal of Neuroimmune Pharmacology

, Volume 11, Issue 1, pp 1–8 | Cite as

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)

  • P. S. RommerEmail author
  • T. Dörner
  • K. Freivogel
  • J. Haas
  • B. C. Kieseier
  • T. Kümpfel
  • F. Paul
  • F. Proft
  • H. Schulze-Koops
  • E. Schmidt
  • H. Wiendl
  • U. Ziemann
  • U. K. Zettl
  • GRAID investigators
BRIEF REPORT

Abstract

Introduction

Multiple sclerosis (MS) is an immune-mediated disease. Over the last decades therapeutic options have broadened tremendously. Nevertheless, various therapeutic agents, e.g., rituximab, are currently used in the treatment of MS off label. Disease or health registries are useful methods to collect information about off-label treatments. The German registry for autoimmune disease (GRAID) is a multicenter, retrospective, non-interventional database of patients with various autoimmune diseases.

Aim/Methods

The aim of this observational analysis is to present safety data of rituximab in the treatment of MS and neuromyelitis optica (NMO) in a real life clinical setting based on the available registry data.

Results

Data were collected nationwide in patients who received rituximab. 56 patients were treated with rituximab for MS or NMO. Average observation period was 9.6 months (SD 7.6, ranging from 6 to 29.7 months). Interval between treatments cycles differed tremendously (ranging from 0 to 21 months, median 10 months). Number of infusions ranged from 1 up to more than 8. The analysis provides experience on almost 50 patient years. Infusion related reactions were most common and reported in four patients; infections were seen in three patients (two of them were hospitalized for urinary tract infection and urosepsis). All patients recovered from infection. Full treatment response was attested in a quarter of the patients; two thirds benefited partially from treatment.

Discussion

Safety data of almost 50 patient years of treatment with rituximab show that rituximab is tolerated well in MS/NMO patients. Infections and infusion reactions are the most common adverse events. Our data may help the individual physician to balance efficacy of rituximab against the risk.

• Data on rituximab in MS and NMO are provided for almost 50 patientyears

• Rituximab was tolerated well

• No unexpected side effects were seen

• Almost 80 % of the patients benefited at least partially from treatment

Keywords

Multiple sclerosis Neuromyelitis optica Treatment Rituximab 

Notes

Acknowledgments

We want to thank Jens Westphal, MD and Waltraud Jakob for their support in the collection of patients’ data.

Compliance with Ethical Standards

Potential Conflicts of Interests

TD received study support from Roche; consulting fees or honoraria from Roche, Chugai, UCB, J&J, Eli Elly; payment for lectures including service on speakers bureau from Roche, Chugai, UCB, Sanofi, J&J, Eli Elly. FrP received grants from the Guthy Jackson Charitable foundation; grant application is underway to Alexion pharmaceuticals; FrP received consulting fees or honoraria from Alexion, Chugai and MedImmune. HW received compensation for serving on Scientific Advisory Boards/Steering Committees for Bayer Healthcare, Biogen Idec, Genzyme, Merck Serono, Novartis and Sanofi Aventis. He has received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen Idec, CSL Behring, Fresenius Medical Care, Genzyme, Glaxo Smith Kline, GW Pharmaceuticals, Lundbeck, Merck Serono, Omniamed, Novartis and Sanofi Aventis. He has received compensation as a consultant from Biogen Idec, Merck Serono, Novartis and Sanofi Aventis, received research support from Bayer Vital, Biogen Idec, Genzyme Merck Serono, Novartis, Sanofi Aventis Germany, Sanofi US. All the other authors report no potential conflicts of interest.

The study was supported in part by an unrestricted educational grant by Roche Pharma AG Germany.

References

  1. Beres SJ, Graves J, Waubant E (2014) Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 51(1):114–118CrossRefPubMedGoogle Scholar
  2. Boster A, Ankeny DP, Racke MK (2010) The potential role of B cell-targeted therapies in multiple sclerosis. Drugs 70:2343–2356CrossRefPubMedGoogle Scholar
  3. Carmona L, de la Vega M, Ranza R, Casado G, Titton DC, Descalzo MÁ, Gómez-Reino J (2014) BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol 32(5 Suppl 85):S-163–S-167Google Scholar
  4. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517CrossRefPubMedGoogle Scholar
  5. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270–1272CrossRefPubMedGoogle Scholar
  6. Cross AH, Waubant E (2011) MS and the B cell controversy. Biochim Biophys Acta 1812:231–238CrossRefPubMedGoogle Scholar
  7. Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I (2014) The off-label use of targeted therapies in sarcomas: the OUTC’S program. BMC Cancer 14:870. doi: 10.1186/1471-2407-14-870 PubMedCentralCrossRefPubMedGoogle Scholar
  8. Ehler J, Koball S, Sauer M, Hickstein H, Mitzner S, Benecke R, Zettl UK (2014) Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Ther Apher Dial 18(5):489–496CrossRefPubMedGoogle Scholar
  9. Emery P, Gallo G, Boyd H, Morgan CL, Currie CJ, Poole CD, Nab HW (2014) Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 32(5):653–660PubMedGoogle Scholar
  10. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688CrossRefPubMedGoogle Scholar
  11. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460–471CrossRefPubMedGoogle Scholar
  12. He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (2013) Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 12, CD009130PubMedGoogle Scholar
  13. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443–1448CrossRefPubMedGoogle Scholar
  14. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl UUK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. doi: 10.1186/1742-2094-9-14 PubMedCentralCrossRefPubMedGoogle Scholar
  15. Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176(2):149–164PubMedCentralCrossRefPubMedGoogle Scholar
  16. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117CrossRefPubMedGoogle Scholar
  17. Koch-Henriksen N, Magyari M, Laursen B (2015) Registers of multiple sclerosis in Denmark. Acta Neurol Scand 132(199):4–10. doi: 10.1111/ane.12424 CrossRefPubMedGoogle Scholar
  18. Krumbholz M, Meinl E (2014) B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 36(3):339–350CrossRefPubMedGoogle Scholar
  19. Kutzelnigg A, Lassmann H (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 122:15–58CrossRefPubMedGoogle Scholar
  20. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMedGoogle Scholar
  21. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907–911CrossRefPubMedGoogle Scholar
  22. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8(9):913–919CrossRefPubMedGoogle Scholar
  23. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62(2):258–264CrossRefPubMedGoogle Scholar
  24. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74(23):1860–1867PubMedCentralCrossRefPubMedGoogle Scholar
  25. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952CrossRefPubMedGoogle Scholar
  26. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315CrossRefPubMedGoogle Scholar
  27. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846CrossRefPubMedGoogle Scholar
  28. Rommer PS, Stüve O (2013) Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol 15(3):241–258CrossRefPubMedGoogle Scholar
  29. Rommer PS, Patejdl R, Winkelman A, Benecke R, Zettl UK (2011) Rituximab for secondary progressive multiple sclerosis: a case series. CNS Drugs 25:607–613CrossRefPubMedGoogle Scholar
  30. Rommer PS, Patejdl R, Zettl UK (2012) Monoclonal antibodies in the treatment of neuroimmunological diseases. Curr Pharm Des 18(29):4498–4507CrossRefPubMedGoogle Scholar
  31. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O (2014) Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 175(3):397–407PubMedCentralCrossRefPubMedGoogle Scholar
  32. Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T, GRAID investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75PubMedCentralCrossRefPubMedGoogle Scholar
  33. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T, Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16PubMedCentralCrossRefPubMedGoogle Scholar
  34. Wahren-Herlenius M, Dörner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382(9894):819–831CrossRefPubMedGoogle Scholar
  35. Waubant E (2008) Spotlight on anti-CD20. Int MS J 15:19–25PubMedGoogle Scholar
  36. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114CrossRefPubMedGoogle Scholar
  37. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489CrossRefPubMedGoogle Scholar
  38. Zettl UK, Stüve O, Patejdl R (2012) Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11(3):167–173CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • P. S. Rommer
    • 1
    • 2
    Email author
  • T. Dörner
    • 3
  • K. Freivogel
    • 4
  • J. Haas
    • 5
  • B. C. Kieseier
    • 6
  • T. Kümpfel
    • 7
  • F. Paul
    • 8
  • F. Proft
    • 9
  • H. Schulze-Koops
    • 9
  • E. Schmidt
    • 4
  • H. Wiendl
    • 10
  • U. Ziemann
    • 11
    • 12
  • U. K. Zettl
    • 1
  • GRAID investigators
  1. 1.Department of Neurology, Neuroimmunological SectionUniversity of RostockRostockGermany
  2. 2.Department of NeurologyMedical University of ViennaViennaAustria
  3. 3.Department of Medicine/Rheumatology and Clinical ImmunologyCharité – Universitätsmedizin BerlinBerlinGermany
  4. 4.Analytica GmbHLörrachGermany
  5. 5.Department of NeurologyJewish Hospital BerlinBerlinGermany
  6. 6.Department of Neurology, Medical FacultyHeinrich Heine-UniversityDüsseldorfGermany
  7. 7.Institute of Clinical NeuroimmunologyLudwig-Maximilians-UniversityMunichGermany
  8. 8.NeuroCure Clinical Research CenterCharité – Universitätsmedizin BerlinBerlinGermany
  9. 9.Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IVUniversity of MunichMunichGermany
  10. 10.Department of NeurologyUniversity of MuensterMuensterGermany
  11. 11.Department of Neurology & Stroke, Hertie Institute for Clinical Brain ResearchEberhard-Karls-UniversityTübingenGermany
  12. 12.Department of NeurologyGoethe University FrankfurtFrankfurt/MainGermany

Personalised recommendations